Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol

Archives of General Psychiatry

Volumn 55, Issue 3, 1998, Pages 250-258

  Tollefson, Gary D ^a   Sanger, Todd M ^a   Lu, Yili ^a   Thieme, Martha E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; DRUG RESPONSE; DRUG SCREENING; EXTRAPYRAMIDAL SYMPTOM; PRIORITY JOURNAL;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COMORBIDITY; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; PIRENZEPINE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0032498873     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.55.3.250     Document Type: Article

References (63)

1. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia: methods, meanings, and mechanisms. Arch Gen Psychiatry. 1995;52:341-351.
2. Bleuler E. Dementia Praecox or the Group of Schizophrenias. New York. NY: International Universities Press: 1950.
3. McGlashan TH, Carpenter WT Jr. An investigation of the post psychotic depressive syndrome. Am J Psychiatry. 1976;133:14-19.
4. Birchwood M. Mason R, Macmillan F, Heaiy J. Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med. 1993;23:387-395.
5. Roy A, Thompson R, Kennedy S. Depression in chronic schizophrenia. Br J Psychiatry. 1983;142:465-470.
6. Siris SG. Depression and schizophrenia. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Oxford, England: Blackwell Science Ltd; 1995:128-145.
7. Hirsch SR, Jolley AG. The dysphoric syndrome in schizophrenia and its implications for relapse. Br J Psychiatry. 1989;155(suppl 5):46-50.
8. Johnson DAW. The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry. 1988;152:320-323.
9. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J. Depression in first-episode schizophrenia. Am J Psychiatry. 1993;150:1643-1648.
10. Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet. 1995;345 (8949):557-562.
11. Hyman S, How antidepressants might work. Prog Notes. 1995;6:11-15.
12. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14;87-96.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
14. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465.
15. Overall JE, Gorham DR. Brief Psychiatric Rating Scale (BPRS). Psychol Rep. 1962;10:799-812.
16. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
17. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, Inc; 1986.
18. Guy W. ECDEU Assessment Manual for Psychopharmacology. Bethesda, Md: US Dept of Health, Education and Welfare; 1976.
19. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;212(suppl):11-19.
20. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
21. SAS Institute Inc. SAS/STAT User's Guide. Vol 1 & 2. 4th ed, 6th version. Gary, NC: SAS Institute Inc; 1990.
22. Retherford RD, Kim Choe M. Path analysis. In: Statistical Models for Causal Analysis. New York, NY: John Wiley & Sons Inc; 1993:93-99.
23. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr Scand. 1978;271(suppl):5-27.
24. Snaith P. What do depression rating scales measure? Br J Psychiatry. 1993;163:293-298.
25. Galinowski A, Lehert P. Structural validity of MADRS during antidepressant treatment, lut Clin Psychopharmacol. 1995;10:157-161.
26. Montgomery SM. Depressive symptoms in acute schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 1979;3:429-433.
27. Burrows GD, Norman TR. Affective mood disturbance in schizophrenia. In: Ancill R, ed. Schizophrenia: Exploring the Spectrum of Psychosis. West Sussex, England: John Wiley & Sons Ltd; 1994:205-214.
28. Knights A, Okasha MS, Salih MA, Hirsch SR. Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients. Br J Psychiatry. 1979;135:515-523.
29. Johnson DAW. Depressions in schizophrenia: some observations on prevalence, etiology, and treatment. Acta Psychiatr Scand. 1981;63(suppl 291):137-144.
30. Martin RL, Clontnger RC, Guze SB, Clayton PJ. Frequency and differential diagnosis of depressive syndromes in schizophrenia. J Clin Psychiatry. 1985;46:9-13.
31. Leff J, Tress K, Edwards B. The clinical course of depressive symptoms in schizophrenia. Schizophr Res. 1988;1:25-30.
32. Roy A. Do neuroleptics cause depression? Biol Psychiatry. 1984;19:777-781.
33. Berrios GE, Bulbena A. Postpsychotic depression: the Fulburn cohort. Acta Psy chiatr Scand. 1987;76:89-93.
34. Siris SG, Strahan A, Mandefi J. Cooper TB, Casey E. Fluphenazine decanoate dose and severity of depression in patients with postpsychotic depression. Schizophr Res. 1988;1:31-35.
35. Barnes TR, Curson DA, Liddle PF, Patel M, The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry. 1989;154:486-491.
36. Bandelow B, Muller P, Gaebel W, Kopeke W, Linden M, Muller-Spahn F, Pietzcker A, Reischies FM, Tegeler J. Depressive syndromes in schizophrenic patients after discharge from hospital. Eur Arch Psychiatry Clin Neurosci. 1990; 240:113-120.
37. Nelson JC, The use of antipsychotic drugs in the treatment of depression. In: Belmaker RH, ed. Treatment-Resistant Depression. Costa Mesa. Calif: PMA Publishing Corp; 1987:131-146.
38. Roy A, Thompson R, Kennedy S.Depression in chronic schizophrenia. Br J Psychiatry. 1983;142:465-470.
39. Harrow M, Yonan CA, Sands JR, Marengo J. Depression in schizophrenia: are neuroleptics, akinesia, oranhedonia involved? Schizophr Bull. 1994;20:327-338.
40. Galdi J. The causality of depression in schizophrenia. Br J Psychiatry. 1983;142: 621-625.
41. Galdi J, Rieder RO, Silber D, Bonato RR. Genetic factors in the response to neuroleptics in schizophrenia: a pharmacogenetic study. Psychol Med. 1981;11: 713-728.
42. Siris SG. Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull. 1991;17:75-98.
43. Glazer W, Prusoff B, John K. Depression and social adjustment among chronic schizophrenic outpatients. J Nerv Ment Dis. 1981;169:712-717.
44. VanPutten T, May PRA. 'Akinetic depression' in schizophrenia. Arch Gen Psychiatry. 1978;35:1101-1107.
45. Singh AN, Saxena B, Nelson HL. A controlled clinical study of trazodone in chronic schizophrenic patients with pronounced depressive symptomatology. Curr Ther Res. 1978;23:485-501.
46. Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, Hammill K, Carter M, Munetz MR, Perel J. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry. 1995;52:29-41.
47. Prusoff BA, Williams DH, Weissman MM, Astrachan BM. Treatment of secondary depression in schizophrenia. Arch Gen Psychiatry. 1979;36:569-575.
48. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria fora Selected Group of Functional Disorders. 3rd ed. New York, NY: Biometrics Research Division, New York State Psychiatric Institute; 1977.
49. Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB. Adjunctive imipramine in the treatment of postpsychotic depression: a controlled trial. Arch Gen Psychiatry. 1987;44:533-539.
50. Pandey GN, Pandey SC, Janicak PG, Marks RC, Davis JM. Platelet serotonin-2 receptor binding sites in depression and suicide. Biol Psychiatry. 1990;28:215-222.
51. Kahn RS, Davidson M. Serotonin, dopamine and their interactions in schizophrenia: an editorial. Psychopharmacology. 1993;112(suppl):S1-S4.
52. Rifkin A, Quitkin F, Klein D. Akinesia: a poorly recognized drug-induced extra-pyramidal behavioral disorder. Arch Gen Psychiatry. 1975;32:672-674.
53. Rifkin A, Quitkin F, Kane J, Klein DF. Are prophylactic antiparkinsonian drugs necessary? a controlled study of procyclidine withdrawal. Arch Gen Psychiatry. 1978; 35:483-489.
54. Siris SG. Akinesia and postpsychotic depression: a difficult differential diagnosis. J Clin Psychiatry. 1987;48:240-243.
55. Bermanzohn PC, Siris SG. Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. Compr Psychiatry. 1992;33:221-232.
56. Möller HJ, vonZerssen D. Depressive states occurring during the neuroleptic treatment of schizophrenia. Schizophr Bull. 1982;8:109-117.
57. Sands JR, Harrow M. Psychotic unipolar depression at follow-up: factors related to psychosis in the affective disorders. Am J Psychiatry. 1994;151:995-1000.
58. Dollfus S, Petit M, Menard JF. Relationship between depressive and positive symptoms in schizophrenia. J Affect Dis. 1993;28:61-69.
59. Sax KW, Strakowski SM, Keck PE Jr, Upadhyaya VH, West SA, McElroy SL Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. Br J Psychiatry. 1996;168:68-71.
60. Whiteford HA, Riney SJ, Csernansky JG. Distinguishing depressive and negative symptoms in chronic schizophrenia. Psychopathology. 1976;20:234-236.
61. Kitamura T, Suga R. Depressive and negative symptoms in major psychiatric disorders. Compr Psychiatry. 1991;32:88-94.
62. Kibel DA, Laffont I, Liddle PF. The composition of the negative syndrome of chronic schizophrenia. Br J Psychiatry. 1993;162:744-750.
63. Presser ES, Csernansky JG, Kaplan J, Thiemann S, Becker TJ, Hollister LE. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. J Nerv Ment Dis. 1987;175:100-105.